Tiorfan (racecadotril) / Bioprojet 
Welcome,         Profile    Billing    Logout  
 6 Diseases   7 Trials   7 Trials   65 News 


12»
  • ||||||||||  Tiorfan (racecadotril) / Bioprojet
    Review, Journal:  Racecadotril in the management of diarrhea: an underestimated therapeutic option? (Pubmed Central) -  Jan 12, 2025   
    Racecadotril has been shown to increase the likelihood of home management of AID, to reduce hospitalizations and parenteral rehydration needs resulting in healthcare costs reduction. The current new formulations require only two-daily doses for adults and the pediatric syrup should simplify its use.
  • ||||||||||  Tiorfan (racecadotril) / Bioprojet
    Journal:  Efficacy of Racecadotril in a Patient Affected by a Therapy-Refractory VIPoma and Carcinoid Syndrome. (Pubmed Central) -  Oct 1, 2024   
    After 5 days of treatment, the WDHA syndrome exhibited sufficient control, facilitating the patient's discharge from the ICU. This case report underscores racecadotril as an individualized, off-label treatment strategy for patients with severe VIPoma and serotonin-driven WDHA syndrome, where conventional therapeutic avenues have been exhausted.
  • ||||||||||  Review, Journal:  New and Emerging Therapeutic Drugs for the Treatment of Pulmonary Arterial Hypertension: A Systematic Review. (Pubmed Central) -  Sep 30, 2024   
    Conversely, udenafil, racecadotril, sotatercept, anastrozole, riociguat, tacrolimus, and ralinepag were found to be safe, well-tolerated, and effective in improving hemodynamic measures and 6-MWDs. This study aims to summarize the developing treatment options currently under clinical trials, highlighting the need for further trials before their application in clinical practice.
  • ||||||||||  Tiorfan (racecadotril) / Bioprojet
    EFFICACY OF RACECADOTRIL IN A NEN PATIENT SUFFERING FROM THERAPY-REFRACTORY VIPOMA AND CARCINOID-SYNDROM (Science Lounge) -  Jul 18, 2024 - Abstract #UEGW2024UEGW_931;    
    This case report underscores racecadotril as an individualized, off-label treatment strategy for patients with severe VIPoma and serotonin-driven WDHA syndrome, where conventional therapeutic avenues have been exhausted. Further studies are warranted to potentially expand and license the use of Racecadotril in this indication.
  • ||||||||||  Tiorfan (racecadotril) / Bioprojet
    Trial completion date, Trial primary completion date:  Influence of NEP Inhibition on Vascular Leak and Inflammation (NEPi-INFLAMMATION) (clinicaltrials.gov) -  Nov 18, 2023   
    P=N/A,  N=48, Recruiting, 
    As a result, it can be stated that racecadotril, which has an antisecretory effect, is beneficial in the treatment of bacterial diarrhea caused by such as E. coli. Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jan 2025 --> Jan 2026
  • ||||||||||  Tiorfan (racecadotril) / Bioprojet
    Trial initiation date:  Influence of NEP Inhibition on Vascular Leak and Inflammation (NEPi-INFLAMMATION) (clinicaltrials.gov) -  Sep 14, 2023   
    P=N/A,  N=48, Recruiting, 
    Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jan 2025 --> Jan 2026 Initiation date: May 2023 --> Aug 2023
  • ||||||||||  Tiorfan (racecadotril) / Bioprojet
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date:  Influence of NEP Inhibition on Vascular Leak and Inflammation (NEPi-INFLAMMATION) (clinicaltrials.gov) -  Apr 3, 2023   
    P=N/A,  N=48, Recruiting, 
    Initiation date: May 2023 --> Aug 2023 Not yet recruiting --> Recruiting | Trial completion date: Mar 2024 --> Jun 2025 | Initiation date: Jan 2023 --> May 2023 | Trial primary completion date: Jan 2024 --> Jan 2025
  • ||||||||||  Tiorfan (racecadotril) / Bioprojet
    Journal:  Integrating metabolomics, bionics, and culturomics to study probiotics-driven drug metabolism. (Pubmed Central) -  Feb 14, 2023   
    However, a personalized effect was observed in the racecadotril-metabolizing activity of L. casei Zhang, depending on the individual's host gut microbiome composition. Based on data generated by our workflow, we proposed a possible mechanism of interactions among L. casei Zhang, racecadotril, and host gut microbiome, providing practical guidance for probiotic-drug co-treatment and novel insights into precision probiotics.
  • ||||||||||  Tiorfan (racecadotril) / Bioprojet
    PK/PD data, Journal:  Can diarrhea affect the pharmacokinetics of racecadotril in neonatal calves? (Pubmed Central) -  Sep 10, 2022   
    As in calves with infectious diarrhea, thiorphan in plasma was only detected in healthy calves from 0.25 to 1.5 h. Racecadotril showed a large distribution volume, rapid elimination, and low metabolism to thiorphan in healthy calves.
  • ||||||||||  Tiorfan (racecadotril) / Bioprojet
    Journal:  Evaluation of the Effect of Ethyl Acrylate-Methyl Methacrylate Copolymer in Racecadotril Dispersible Tablet. (Pubmed Central) -  Sep 2, 2022   
    Our results demonstrated that a chemically long-term stable racecadotril dispersible tablet product, whose taste is efficiently masked using wet granulation method with an acceptable release profile was obtained with Eudragit NE 30D ratio higher than 1% and equal or lower than 10% by weight of racecadotril. The developed formulation can increase patient compliance.
  • ||||||||||  metoclopramide / Generic mfg., apremilast / Generic mfg.
    A Multinational Chart Review to Examine Gastrointestinal Symptoms and Their Management in Patients Treated with Apremilast for Plaque Psoriasis () -  Mar 21, 2022 - Abstract #AAD2022AAD_2561;    
    The following GI symptoms were reported: ‒ Diarrhea (US: 67% [331/494]; France: 76% [97/128]) with median time from onset to resolution/improvement of 26 days (US) and 21 days (France) ‒ Nausea (US: 52% [255/494]; France: 34% [44/128]) with median time from onset to resolution/improvement of 21 days (US) and 24 days (France)Management strategies for diarrhea included pharmacologic (loperamide/bismuth subsalicylate/racecadotril) with or without non-pharmacologic (dietary modifications, taking with food)/fiber (US: 30% [99/331], France: 41% [40/97]) and non-pharmacologic only (US: 32% [105/331], France: 27% [26/97]). Recommendations to manage diarrhea and nausea after apremilast initiation with pharmacologic or non-pharmacologic strategies were effective and symptoms usually resolved within 3-4 weeks of onset.
  • ||||||||||  Tiorfan (racecadotril) / Bioprojet
    Journal:  Design, synthesis, and evaluation of novel racecadotril-tetrazole-amino acid derivatives as new potent analgesic agents. (Pubmed Central) -  Aug 28, 2021   
    The negative and high binding energy of docking simulation of the most potent compounds in the catalytic site of neprilysin was also in good agreement with the inhibitory activity of test compounds. Racecadotril-tetrazole-amino acid derivatives, as potential antinociceptive agents, demonstrated moderate to good antinociceptive activities comparable with morphine and higher than racecadotril.
  • ||||||||||  Tiorfan (racecadotril) / Bioprojet
    Journal:  Drugs in Focus: The Use of Racecadotril in Paediatric Gastrointestinal Disease. (Pubmed Central) -  Jun 22, 2021   
    No serious adverse events related to racecadotril have been reported.Racecadotril has proven its efficacy as an adjuvant antidiarrhoeal drug with a good safety profile. Its addition to oral rehydration solution (ORS) appears clinically beneficial and potentially leads to health care savings.
  • ||||||||||  Lopressor (metoprolol tartrate) / Novartis, Tenormin (atenolol) / AstraZeneca, Tiorfan (racecadotril) / Bioprojet
    Journal:  Dispersive solid-phase extraction of racemic drugs using chiral ionic liquid-metal-organic framework composite sorbent. (Pubmed Central) -  Oct 24, 2020   
    As a result, enantiomeric excess values are 90.4%, 95%, 92%, 81.6% and 83.2% for atenolol, propranolol, metoprolol, racecadotril and raceanisodamine, respectively. The developed enantioselective method was validated following ICH guidelines and it was proved to be simple, effective and enantioselective way for separation of racemic pharmaceuticals with similar behaviors.
  • ||||||||||  Tiorfan (racecadotril) / Bioprojet
    Clinical, Review, Journal:  Racecadotril for acute diarrhoea in children. (Pubmed Central) -  May 2, 2020   
    Current evidence does not support routine use of racecadotril in management of acute diarrhoea in children under five outside of the context of placebo controlled RCTs. 18 December 2019 Up to date All studies incorporated from most recent search All studies identified during the most recent search (4 Mar, 2019) have been incorporated in the review, and no ongoing studies identified.
  • ||||||||||  Tiorfan (racecadotril) / Bioprojet
    Trial completion date, Trial primary completion date:  Study to Evaluate the Efficacy and Safety of Racecadotril in Children Aged 3 to 60 Months Suffering From Acute Diarrhea (clinicaltrials.gov) -  Jan 30, 2020   
    P3,  N=44, Recruiting, 
    18 December 2019 Up to date All studies incorporated from most recent search All studies identified during the most recent search (4 Mar, 2019) have been incorporated in the review, and no ongoing studies identified. Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020
  • ||||||||||  Tiorfan (racecadotril) / Bioprojet
    Journal:  Drugs in Focus: The Use of Racecadotril in Paediatric Gastrointestinal Disease. (Pubmed Central) -  Dec 5, 2019   
    No serious adverse events related to racecadotril have been reported.Racecadotril has proven its efficacy as an adjuvant anti-diarrhoeal drug with a good safety profile. Its addition to oral rehydration solution (ORS) appears clinically beneficial and potentially leads to health care savings.
  • ||||||||||  ondansetron / generics
    Clinical, Review, Journal:  Management of acute gastroenteritis in children (Pubmed Central) -  Oct 29, 2019   
    Antibiotherapy should be only considered in exceptional situations. Acute diarrhea is commonly known medical problem, which can be easily treated by following simple, well-defined rules.